Patients with depression or diabetes have an increased risk of MI, but the risk is even higher in patients with both conditions, according to a new study.…

Menu labels on college cafeteria food — highlighting the good and the bad of various meal options — make no difference in students’ choices, a new study concludes.…

Discovery makes white fat mimic energy-burning brown fat, muscle.…

There was a news release that caught my attention this past week. Eli Lilly announced that the Exenatide tQT Study Showed No Prolongation of QT Interval (See this week’s Item #1). Back in March most of us thought that the FDA would approve the once weekly dose, but instead they …

This week we examine more of your responses regarding GLP-1 therapy…. See more GLP-1 Agonist Resources. I was glad to see that almost everyone realized that when a GLP-1 agonist is added to a sulfonylurea that it is not the GLP-1 agonist that is responsible for any side effects. It’s …

This week in Part 3 of our Case Study, Mr. Walker and his wife return for a follow-up visit as his glucose control has not improved as much as expected. Click here to see if you agree with the drug choice. In our analysis of the GLP-1 survey data, we …

Exenatide, a GLP-1 receptor agonist, improves glycemic control and body weight with twice daily or once weekly subcutaneous (SC) injections in patients with type 2 diabetes (T2DM)….

Type 2 diabetes mellitus (T2DM) often requires combination therapy to maintain glycemic control. Adding a sulfonylurea to metformin therapy improves glycemic control, but can cause hypoglycemia and weight gain. This 2-yr double-blind trial investigated the long-term efficacy and safety of adding linagliptin or glimepiride to ongoing metformin to treat T2DM….

Exenatide yields beta cell improvement and weight loss in individuals with diabetes but has not been well-studied in individuals with prediabetes….

This randomized, open-label, parallel-group, multicenter, 24-wk main treatment study, followed by a variable extension of at least 52 wk, compared the efficacy and safety of lixisenatide 20 µg QD and exenatide 10 µg BID in 634 T2DM patients insufficiently controlled on metformin ≥1.5 g/day (mean age 57.4 yr, diabetes duration …